Home > media room > Press Release > details

Fund managed and/or advised by Motilal Oswal Private Equity and InvAscent invests in Symbiotec Pharmalab Private Limited

Mumbai 18-Dec-2018

Fund managed and/or advised by Motilal Oswal Private Equity andInvAscent

invests in Symbiotec Pharmalab Private Limited


Motilal Oswal Private Equity (“MOPE”) through its third private equityfund, India Business Excellence Fund – III (‘IBEF-III”), and RosewoodInvestments advised by InvAscent has invested an undisclosed amount in SymbiotecPharmalab Private Limited (“Symbiotec”). Symbiotec, an Indore based company, isengaged in the business of development, manufacturing, marketing and exportingactive pharmaceutical ingredients (APIs) and formulation products. Thetransaction involved a consortium of MOPE and Rosewood buying out stake of existingprivate equity investor Actis and committing further primary investment in thecompany to fuel future growth.

Started in 1995 by AnilSatwani in Indore, Symbiotec has transformed into one of the largestindependent companies in Steroids-Hormones globally. It has a strong customerbase with marquee clients across domestic and global pharmaceutical companies. Companyhas 2 US FDA, EU GMP approved manufacturing facilities in Indore and also hasinvested significantly over the last 3 years on development and manufacturingof formulations particularly for the US market.

Mr. Anil Satwani, Managing Director of Symbiotec says, “Symbiotectoday is poised at an inflection point having largely backward integrated itsAPI business and now is on the cusp of launching its own formulations in the USmarket. Over the last decade, we have partnered with multiple renownedinvestors to fuel our growth aspirations and created value for all thestakeholders. We are pleased to partner with MOPE & InvAscent and stronglybelieve that they are perfect partners for us with their financial, technicalacumen and full alignment with our values and ethos.”

Mr. Vishal Tulsyan, ManagingDirector and CEO of MOPE commented, “Indianpharmaceutical companies continue to gain market share and credibilityworldwide. At MOPE, pharmaceuticals is one of our focus sectors and we continueto look for attractive investment opportunities therein. We are pleased to announceour investment in Symbiotec that presents a unique opportunity to partner withone of the largest vertically integrated company in the niche segment ofsteroids and hormones. Through this partnership, we intend to help Symbiotecachieve its vision of becoming an integrated “farm to pharmacy” company”.


About Motilal Oswal Private Equity

MOPE Investment Advisors Private Limited(MOPE) is a subsidiary of Motilal Oswal Financial Services Limited (MOFSL), adiversified financial services group with businesses in securities, assetmanagement, private equity and investment banking. MOPE is currently managing overINR 6000 Crores (US$ 900 million) across growth capital funds and real estatefunds. The growth capital private equity is focused on providing capital tomid-market companies across sectors and cumulatively has an AuM of around INR4000 crore spread across three funds. MOPE has till date invested in 28companies across financial services, life sciences, niche manufacturing andconsumption based sectors. MOPE recently closed IBEF III at INR 2,300 Crore (US$320 million) from which investments are currently being made.


Forfurther details contact:

Rohini Kute

Head of Corporate Communications, Motilal Oswal Financial Services

Mob +91 9820196838

Mail: rohini.kute@motilaloswal.com

Alpesh Nakrani

Paradigm Shift Public Relations

Mob +91 98691 21167

Ph-   +91 22 2281 3797 / 98